---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027751"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-06-08T21:00:43+00:00"
generated_at: "2026-06-08T21:02:54.360387+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Mira Pharmaceuticals appoints fractional CFO after CFO Weichselbaum departs

## Summary
- Alan Weichselbaum resigned as CFO effective June 6, 2026, with no disagreement with the company.
- Andriy Mushak, CPA with over 20 years SEC experience, appointed fractional CFO effective June 6, 2026.
- Mushak will serve via consulting agreement with LMAM Consulting Group; company to pay $6,000 per month.
- Mushak's expertise includes SEC reporting, audit readiness, internal controls, and capital-markets support.

## SEC filing metadata
- accession: 0001493152-26-027751
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-06-08T21:00:43+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/0001493152-26-027751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027751
- JSON: https://secwatch.observer/filing/0001493152-26-027751.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027751.txt

## Key facts
- Executive change
  Andriy Mushak was appointed as fractional Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: fractional Chief Financial Officer
  source text: On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/0001493152-26-027751-index.htm
- Executive change
  Alan Weichselbaum resigned as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/0001493152-26-027751-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.